Cypherpunk Technologies reports Q2 2026 financial results

Cypherpunk Technologies Inc. has released its financial results for the second quarter of 2026. A key component of the report is the company’s Zcash digital asset treasury strategy, which has seen holdings increase to 323,394.38 ZEC. As of August 11, 2026, this amount represents approximately 1.92% of the total circulating supply of the Zcash network, with an average purchase price of $341.83 per unit.

Additionally, the company’s subsidiary, Leap Therapeutics, has reached an agreement with the FDA regarding a proposed Phase 3 clinical trial. The trial focuses on a DKK1-high, second-line, metastatic colorectal cancer population. The company is currently evaluating strategic options for its sirexatamab treatment, including a potential independently financed spin-out or a partnership to advance the drug.